Quarterly financial reporting / Third quarter financial report
16/11/2026 18:00Information financière trimestrielleInformations réglementées supplémentaires devant être rendues publiques en vertu de la législation d'un état membre
AMFImmediate publication
“Company”), a late-stage clinical biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today reported its cash position and revenues as of September 30, 2026.
Press release
MaaT Pharma Reports Financial Results for the Third Quarter 2026
- Revenues of EUR 0.5 million in the third quarter of 2026 and EUR 1.6 million year-todate, derived from the Early Access Program
- As of September 30, 2026, cash and cash equivalents were EUR 10.1 million, not including the EUR 3.7 million 2025 Research Tax Credit, received by the Company in
October 2026
- Cash runway estimated through the end of December 2026, based on the
Company’s current operating plan and financial obligations
- The Company continues to actively explore financing opportunities from investors and strategic partnerships
Lyon, France, November 16, 2026, 6:00 pm CET– MaaT Pharma (EURONEXT: MAAT – the
“Company”), a late-stage clinical biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today reported its cash position and revenues as of September 30, 2026.
Cash position1
- As of September 30, 2026, total cash and cash equivalents were EUR 10.1 million (as compared to EUR 24.9 million as of December 31, 2025).
- Taking into account the EUR 3.7 million 2025 Research Tax Credit received in October 2026, the Company estimates that its existing cash resources will fund operations through the end of December 2026, based on its current operating plan and financial obligations. Revenues in Q3 20261
- MaaT Pharma reported revenues of EUR 0.5 million for the third quarter of 2026, and revenues of EUR 1.6 million for the first nine months of 2026.
1 unaudited financial results
Press release
- Since January 2026 and following the transition of the EAP program to Clinigen, MaaT Pharma has been selling the product to Clinigen, which then supplies hospitals in Europe. As a result, revenues generated by the Company are now based on the financial terms of the licensing agreement. Consequently, the net revenue reported by MaaT Pharma for the first nine months of 2026, based on transfer price and royalties, was EUR 1.6 million, and would have been EUR 3.3 million pre-transition, broadly stable compared with EUR 3.4 million in the first nine months of 2025.
Upcoming conferences*
- November 16-18, 2026: ESMO AI Conference in Berlin, Germany